Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 422
- Registration Number
- NCT01119066
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
- Conditions
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Everett Meyer
- Target Recruit Count
- 10
- Registration Number
- NCT01050764
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2017-08-23
- Target Recruit Count
- 126
- Registration Number
- NCT01011920
- Locations
- ๐จ๐ญ
IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
๐ฎ๐นA.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
๐ฉ๐ชUniklinik Freiburg, Freiburg, Germany
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 176
- Registration Number
- NCT01010217
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 44
- Registration Number
- NCT00978471
- Locations
- ๐ซ๐ท
CHU Besanรงon- Hรดpital Jean Minjoz, Besancon, France
๐ซ๐ทChu - Hopital Des Enfants Bordeaux, Bordeaux, France
๐ซ๐ทCHU Dijon Le Bocage, Hรดpital d'Enfants, Dijon, France
Infusion of Expanded Cord Blood T Cells
- Conditions
- Interventions
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00972101
Pilot Study of Unrelated Cord Blood Transplantation
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT00916045
- Locations
- ๐ฌ๐ง
King's College Hosptial NHS Foundation Trust, London, United Kingdom
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
- Conditions
- Interventions
- Drug: Fludarabine PhosphateDrug: TacrolimusDrug: ThiotepaRadiation: Total-Body Irradiation (TBI)Other: Magnetic Affinity Cell SortingProcedure: Peripheral Blood Stem Cell TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00914940
- Locations
- ๐บ๐ธ
Yale University School of Medicine/Yale New Haven Hospital, New Haven, Connecticut, United States
๐บ๐ธFred Hutchinson Cancer Research Center, Seattle, Washington, United States
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00867178
- Locations
- ๐บ๐ธ
Children's National Medical Center, Washington, District of Columbia, United States
๐บ๐ธLurie Children's Hospital-Chicago, Chicago, Illinois, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00857389
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.